Buoyed by the Baxalta integration, Shire’s Q1 top-line more than doubled to $3.6bn, with product sales coming in at $3.4bn. The legacy franchise of Shire delivered 11% growth to $1.8bn, while Baxalta’s legacy business grew by 8% on a pro forma basis to $1.6bn. Within Shire, the growth was driven primarily by a strong performance in Genetic diseases (+14%; 19% of group sales) while Neuroscience (+4%; 18% of group sales) and Internal medicines remained steady (+9%; 12% of group sale
10 May 2017
One-offs fuel a strong performance; fundamentals stable
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
One-offs fuel a strong performance; fundamentals stable
Shires Income PLC GBP (SHRS:LON) | 242 0 0.0% | Mkt Cap: 100.1m
- Published:
10 May 2017 -
Author:
Kamla Singh -
Pages:
3
Buoyed by the Baxalta integration, Shire’s Q1 top-line more than doubled to $3.6bn, with product sales coming in at $3.4bn. The legacy franchise of Shire delivered 11% growth to $1.8bn, while Baxalta’s legacy business grew by 8% on a pro forma basis to $1.6bn. Within Shire, the growth was driven primarily by a strong performance in Genetic diseases (+14%; 19% of group sales) while Neuroscience (+4%; 18% of group sales) and Internal medicines remained steady (+9%; 12% of group sale